At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 43 enrolled
Drug / intervention
Bevacizumab (Avastin) +2 moredrug
Likely dose
Bevacizumab (Avastin) 15 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Evaluation of Avastin in Combination With Docetaxel and Carboplatin as Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Bevacizumab (Avastin), Carboplatin, and 1 other intervention for Non-Small Cell Lung Cancer. Completed, enrolled 43 participants across 2 sites.
Detailed Summary
The goal of this clinical research study is to evaluate the effectiveness of Avastin® in combination with docetaxel and carboplatin in the treatment of lung cancer. The safety of this combination will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2005
First PostedJan 2006
Primary CompletionJul 2017
TodayJul 2026
First PostedJan 2, 2006
Enrollment StartDec 5, 2005
Primary CompletionJul 27, 2017
TodayJul 2, 2026
Enrollment to primary: 11.6 yearsPosted 20.5 years ago
Interventions
Bevacizumab (Avastin)drug
15 mg/kg intravenously (IV) every 3 weeks
Carboplatindrug
AUC 6 IV every 3 weeks
Docetaxeldrug
75 mg/m2 IV every 3 weeks